CN106456565A - 半氟化烷烃在透皮治疗系统中的用途 - Google Patents
半氟化烷烃在透皮治疗系统中的用途 Download PDFInfo
- Publication number
- CN106456565A CN106456565A CN201580025695.1A CN201580025695A CN106456565A CN 106456565 A CN106456565 A CN 106456565A CN 201580025695 A CN201580025695 A CN 201580025695A CN 106456565 A CN106456565 A CN 106456565A
- Authority
- CN
- China
- Prior art keywords
- active substance
- tts
- sfa
- tts according
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Abstract
Description
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14168081.9 | 2014-05-13 | ||
EP14168081.9A EP2944324A1 (de) | 2014-05-13 | 2014-05-13 | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
PCT/EP2015/000937 WO2015172872A1 (de) | 2014-05-13 | 2015-05-07 | Verwendung von semifluorierten alkanen in transdermalen therapeutischen systemen |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106456565A true CN106456565A (zh) | 2017-02-22 |
Family
ID=50731930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580025695.1A Pending CN106456565A (zh) | 2014-05-13 | 2015-05-07 | 半氟化烷烃在透皮治疗系统中的用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170182060A1 (zh) |
EP (2) | EP2944324A1 (zh) |
JP (1) | JP6637907B2 (zh) |
KR (1) | KR102341106B1 (zh) |
CN (1) | CN106456565A (zh) |
AU (1) | AU2015258459B2 (zh) |
CA (1) | CA2948684C (zh) |
ES (1) | ES2895481T3 (zh) |
WO (1) | WO2015172872A1 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
WO2013110621A1 (en) | 2012-01-23 | 2013-08-01 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
JP6039152B2 (ja) | 2012-09-12 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ素化アルカン組成物 |
KR102272568B1 (ko) | 2013-07-23 | 2021-07-05 | 노바리크 게엠베하 | 안정화 항체 조성물 |
CN108349855B (zh) | 2015-09-30 | 2021-07-20 | 诺瓦利克有限责任公司 | 用于眼部给药的半氟化化合物 |
DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
ES2763121T3 (es) | 2016-06-23 | 2020-05-27 | Novaliq Gmbh | Método de administración tópica |
CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
CN110678207A (zh) | 2017-04-21 | 2020-01-10 | 诺瓦利克有限责任公司 | 碘组合物 |
US10717691B2 (en) | 2017-05-05 | 2020-07-21 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
CN111372566A (zh) | 2017-09-27 | 2020-07-03 | 诺瓦利克有限责任公司 | 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物 |
CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
SG11202007858VA (en) | 2018-03-02 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
AU2019345929B2 (en) * | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
KR20210068033A (ko) | 2018-09-27 | 2021-06-08 | 노바리크 게엠베하 | 지질 장벽 수복 |
SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US6262126B1 (en) * | 1995-09-29 | 2001-07-17 | Hasso Meinert | Semi-fluorinated alkanes and their use |
WO2012160180A2 (en) * | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
CN103596554A (zh) * | 2011-05-25 | 2014-02-19 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3046346B2 (ja) * | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
DE10042412B4 (de) | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
DE102005050431A1 (de) | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
EP2332525A1 (en) * | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
US20130338122A1 (en) * | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
-
2014
- 2014-05-13 EP EP14168081.9A patent/EP2944324A1/de not_active Withdrawn
-
2015
- 2015-05-07 EP EP15722654.9A patent/EP3142648B1/de active Active
- 2015-05-07 CN CN201580025695.1A patent/CN106456565A/zh active Pending
- 2015-05-07 JP JP2016567628A patent/JP6637907B2/ja active Active
- 2015-05-07 CA CA2948684A patent/CA2948684C/en active Active
- 2015-05-07 KR KR1020167034687A patent/KR102341106B1/ko active IP Right Grant
- 2015-05-07 AU AU2015258459A patent/AU2015258459B2/en active Active
- 2015-05-07 US US15/309,595 patent/US20170182060A1/en active Pending
- 2015-05-07 ES ES15722654T patent/ES2895481T3/es active Active
- 2015-05-07 WO PCT/EP2015/000937 patent/WO2015172872A1/de active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US6262126B1 (en) * | 1995-09-29 | 2001-07-17 | Hasso Meinert | Semi-fluorinated alkanes and their use |
WO2012160180A2 (en) * | 2011-05-25 | 2012-11-29 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
CN103596554A (zh) * | 2011-05-25 | 2014-02-19 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
JP6637907B2 (ja) | 2020-01-29 |
US20170182060A1 (en) | 2017-06-29 |
KR102341106B1 (ko) | 2021-12-20 |
EP2944324A1 (de) | 2015-11-18 |
EP3142648B1 (de) | 2021-09-29 |
EP3142648A1 (de) | 2017-03-22 |
ES2895481T3 (es) | 2022-02-21 |
AU2015258459B2 (en) | 2020-05-28 |
CA2948684A1 (en) | 2015-11-19 |
WO2015172872A1 (de) | 2015-11-19 |
CA2948684C (en) | 2023-04-18 |
AU2015258459A1 (en) | 2016-12-22 |
KR20170005087A (ko) | 2017-01-11 |
JP2017515855A (ja) | 2017-06-15 |
BR112016026354A8 (pt) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106456565A (zh) | 半氟化烷烃在透皮治疗系统中的用途 | |
US10709669B2 (en) | Microreservoir system based on polysiloxanes and ambiphilic solvents | |
JP4628673B2 (ja) | 活性成分フェンタニルを含む経皮治療システム(tts) | |
ES2326043T3 (es) | Sistema terapeutico percutaneo para la administracion de principios activos lipofilos y/o poco permeables a la piel. | |
ES2599802T3 (es) | Sistema de administración transdérmica | |
CA2948219C (en) | Method for adjusting the release of active agent in a transdermal delivery system | |
IL147247A (en) | The mikveh micro-system is based on polysiloxanes and ambiphilic solvents | |
US6440453B1 (en) | Transdermal systems for release of 5-HT3 receptor antagonists and their use in anti-emetic treatment | |
KR100624500B1 (ko) | 레리세트론 전달용 경피치료시스템 | |
KR100929560B1 (ko) | 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제 | |
ES2900255T3 (es) | Sistema de administración transdérmica que incluye un emulsionante | |
KR20090101579A (ko) | 펜타닐을 함유한 경피 흡수제 | |
KR960021015A (ko) | 경피투여용 패취제제 | |
BR112016026354B1 (pt) | Sistema terapêutico transdérmico e uso de alcanos semifluorados em tal sistema | |
WO2023062201A1 (en) | Transdermal therapeutic system for the transdermal administration of tizanidine | |
WO2023144276A1 (en) | Transdermal therapeutic system for the transdermal administration of selexipag | |
BR112016027143B1 (pt) | Uso de um aditivo em um sistema terapêutico transdérmico, e método para ajuste do período de permeação de um sistema terapêutico transdérmico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB03 | Change of inventor or designer information |
Inventor after: S. Weidesiboge Inventor after: B gancel Inventor after: D. Shrerell Inventor before: S. Weidesiboge |
|
COR | Change of bibliographic data | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171124 Address after: German Adner Beh Applicant after: LTS Lohmann Therapie-Systeme AG Applicant after: Novak Co., Ltd. Address before: German Adner Beh Applicant before: LTS Lohmann Therapie-Systeme AG |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
RJ01 | Rejection of invention patent application after publication |